Nuclide raises 5m

Nuclide Therapeutics builds leaner radiopharmaceuticals

Nuclide Therapeutics raised £5 million to initiate its first clinical trial for anticancer radiopharmaceuticals utilizing theranostic molecules. The London-based firm targets dosing its first patient